Olipudase alfa (Xenpozyme, Sanofi) is indicated 'as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B'.
The dosage schedule is available in the summary of product characteristics for olipudase alfa.
The list price of olipudase alfa is £3,612.00 per 20‑mg vial (excluding VAT, BNF online, accessed November 2024).
The company has a commercial arrangement, which would have applied if olipudase alfa had been recommended.